Incyte (INCY) Short-term Investments (2010 - 2026)
Incyte's (INCY) quarterly Short-term Investments came in at $553.4 million in Q2 2026, up 18.55% YoY from $466.8 million in Q2 2025, and little changed on a QoQ basis from $554.7 million in Q1 2026.
Analysis
Incyte (INCY) Short-term Investments (2010 - 2026) Analysis & Trends
Incyte (INCY) has 17 years of Short-term Investments data on file, last reported at $553.4 million in Q2 2026.
- Quarterly Short-term Investments rose 18.55% year-over-year to $553.4 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $553.4 million (up 18.55% YoY) and the FY2025 annual result came in at $482.8 million, up 2.66% from the prior year.
- Short-term Investments steadied at $553.4 million in Q2 2026, from $554.7 million in the prior quarter.
- In the past five years, Short-term Investments ranged from a high of $554.7 million in Q1 2026 to a low of $286.5 million in Q3 2022.
- A 5-year average of $409.3 million and a median of $464.5 million in 2024 frame the typical range for Short-term Investments.
- Annual changes were most pronounced in 2024 — Short-term Investments soared 72.97% — and 2025, when it fell 7.44%.
- Tracing INCY's Short-term Investments over 5 years: stood at $287.5 million in 2022, then soared by 53.95% to $442.7 million in 2023, then gained by 6.23% to $470.3 million in 2024, then climbed by 2.66% to $482.8 million in 2025, then gained by 14.62% to $553.4 million in 2026.
- The last three Short-term Investments figures came in at $553.4 million (Q2 2026), $554.7 million (Q1 2026), and $482.8 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Incyte | 25.44 Bn | 20.91 Bn | 1.57 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 553.37 Mn |
| Mar 31, 2026 | 554.71 Mn |
| Dec 31, 2025 | 482.79 Mn |
| Sep 30, 2025 | 474.81 Mn |
| Jun 30, 2025 | 466.77 Mn |
| Mar 31, 2025 | 466.94 Mn |
| Dec 31, 2024 | 470.26 Mn |
| Sep 30, 2024 | 467.24 Mn |
| Jun 30, 2024 | 462.21 Mn |
| Mar 31, 2024 | 504.48 Mn |
| Dec 31, 2023 | 442.67 Mn |
| Sep 30, 2023 | 289.22 Mn |
| Jun 30, 2023 | 292.24 Mn |
| Mar 31, 2023 | 291.66 Mn |
| Dec 31, 2022 | 287.54 Mn |
| Sep 30, 2022 | 286.50 Mn |
| Jun 30, 2022 | 287.04 Mn |
| Mar 31, 2022 | 287.40 Mn |
| Dec 31, 2021 | 290.75 Mn |
| Sep 30, 2021 | 285.05 Mn |